Sai Parenterals IPO Review 2026: GMP Flat, Key Investor Insights

Sai Parenterals IPO is open for bidding from 24th March 2026 to 27th March 2026. It is a bookbuilding issue IPO of ₹408.79 crore, the entire and fresh issue of 0.73 crore shares and an offer for sale of 0.32 crore shares. The issue will be listed on BSE and SME on its tentative listing date, 2nd April 2026. 

Sai Parenteral’s IPO Details 

The Sai Parenteral’s IPO date is scheduled from 24th March 2026 to 27th March 2026. The face value of Sai Parenteral’s shares stands at ₹10 per share, and the IPO Issue price band is set at ₹372 to ₹392 per share

Bigshare Services Private Limited is the registrar of the Sai Parenteral’s IPO and is responsible for managing the allotment process and initiating refunds. Check out the latest IPO details in the table below. 

Sai Parenteral’s IPO Share Reservation

Sai Parenteral’s IPO is a bookbuilding issue of 0.17 crore shares, worth ₹21.67 crore. Sai Parenteral’s IPO Limited shares will be listed on the BSE and the SME. Furthermore, SEBI has specified the share reservation criteria for different investor categories. 

Sai Parenteral’s IPO GMP Grey Market Premium

GMP is the gap between the issue price band and the price at which company shares are currently trading in the grey market. Do you want to get live updates on the Sai Parenteral’s IPO? If yes, then you’ve reached the right spot. Check the table below to learn about the GMP trends.

As of 24th March 2026, the Sai Parenteral’s IPO GMP stands at ₹0 per share, indicating the share will likely list at ₹392.00 on its tentative listing date, 2nd April 2026.

GMP data is subject to change based on market trends and sentiments. You should check the live GMP status before applying for the Sai Parenteral’s IPO GMP. Stay informed with Univest for real-time insights into IPOs and their GMP trends. 

Sai Parenteral’s IPO GMP Review

Check out the detailed Sai Parenteral’s GMP IPO review for a thorough understanding of its potential to report listing gains on 1st April 2026. The Sai Parenteral’s IPO review below will help you invest effectively to avoid significant losses. Explore more to make informed investment decisions on this IPO. 

Financial Health

Assess a company’s financial performance to know about its ability to sustain a competitive edge. Thus, it is essential to understand the business’s economic growth and decline before applying for the Sai Parenteral’s IPO.

Sai Parenteral Limited’s revenue increased by 25%, from ₹155.18 crore in March 2024 to ₹163.74 crore in March 2025. Moreover, the company’s PAT increased by 8% from ₹8.42 crore in March 2024 to ₹14.43 crore in March 2025.

Sai Parenteral’s IPO has shown consistent revenue growth, indicating the company’s financial stability. Moreover, brokers, investors, and RAs have a positive outlook for the Sai Parenteral’s IPO, with its tentative listing day set for 2nd April 2026. 

Technical Analysis

Several technical indicators are available to assess a company’s potential to deliver returns. Use the parameters mentioned below to analyse the technicals of the Sai Parenteral’s IPO.

The P/E ratio of Sai Parenteral Limited’s shares is 72.19, and its Earnings Per Share (EPS) stands at 5.43. Thus, the Sai Parenteral’s IPO can deliver gains on its tentative listing date, 2nd April 2026. 

Note: The data, as mentioned above, is taken from authentic sources and highlights pre-issue information. The PE ratio and EPS of Sai Parenteral Limited may change after the IPO. Explore the table below to get post-issue updates on these two metrics. 

Sai Parenteral’s IPO Subscription Status

The Sai Parenteral’s IPO will open for bidding on 24th March 2026. The subscription status for this IPO is yet to be announced. Stay informed on this passage to check the live Sai Parenteral’s IPO Subscription Status. 

About Sai Parenteral’s Limited

Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets. The product portfolio spans multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.

Sai Parenteral’s Limited Financials

The company’s financial analysis is essential before applying for Sai Parenteral’s IPO. See the table for Sai Parenteral’s Limited’s financials. 

Explanation

Sai Parenteral’s Limited’s revenue increased by 5%, from ₹10.99 crore in March 2024 to ₹14.17 crore in March 2025. Moreover, the company’s PAT increased by 4% from ₹2.39 crore in March 2024 to ₹2.52 crore in March 2025.

Sai Parenteral’s Limited IPO Promoter Holdings

Note: The value will be calculated using Equity Dilution = Share Holding Pre Issue – Share Holding Post Issue.

Aim of the Sai Parenteral’s IPO

The primary aim of the Sai Parenteral’s IPO is to raise ₹408.79 crores, and the secondary objective is to:

1. To Repayment or prepayment of all or certain of our borrowings availed by our company
2. Funding Working Capital Requirement of the Company
3. General corporate purposes

Should I Invest in the Sai Parenteral’s IPO?

Explore the pros and cons of Sai Parenteral’s to decide whether to apply or avoid the issue. These pros and cons might help you understand the IPO’s efficiency in delivering profits over the coming decades. 

Pros of the Sai Parenteral’s IPO

• Diversified pharma business (branded generics + CDMO services)
• Strong R&D and manufacturing capabilities
• Wide product portfolio (multiple therapeutic segments)
• IPO funds for expansion, R&D, and capacity growth
• Revenue and profit in recent years
• Presence in domestic + international markets

Cons of the Sai Parenteral’s IPO

• High valuation compared to peers (expensive IPO)
• Margins and return ratios are showing a decline in recent data
• Includes OFS, part of the money goes to existing investors
• Moderate growth (not a very high growth company)
• The pharma sector faces strict regulations & compliance risks
• Dependence on government & institutional orders

How to Apply for the Sai Parenteral’s IPO?

Check the steps mentioned below to apply for Sai Parenteral’s Ltd.

• Step 1: Conduct thorough research on the Sai Parenteral’s IPO GMP, subscription status, issue size, lot size, and other details. 
• Step 2: Open a demat account with Univest to access real-time insights on GMP and subscription status. You can also use your previous demat account by navigating to the IPO section. 
• Step 3: Make a bid for 1 lots of 38 shares worth ₹14,896.
• Step 4: You will receive a mandate request after making a bid. Approve the request to proceed further.    

Note: You can apply for the Sai Parenteral’s IPO across multiple demat accounts to increase your chances of allotment. 

How to Check the Sai Parenteral’s IPO Allotment Status?

You can check for the Sai Parenteral’s IPO allotment in different ways. These include NSE and the registrar portal. Follow the steps below to check your allotment status online.

Check On NSE

• Visit the NSE Official Site
• Navigate to the IPO Allotment Section. 
• Select Equity as the issue type. 
• Choose the Sai Parenteral’s IPO.  
• Choose whether to proceed with the PAN number or the application number.
• Submit your details to get the allotment status online. 

Check On the Registrar Portal

• Visit the registrar portal.
• Click on the allotment option.
• Fill in the required details.
• Click on the submit button to know your Sai Parenteral’s IPO allotment status.

Let’s Wrap

Sai Parenteral’s IPO is a book-building issue of shares worth ₹408.79 crore. The shares of Sai Parenteral Limited will be listed on the BSE and NSE on its tentative listing date of 2nd April 2026. Researching the Sai Parenteral’s IPO GMP and reviews is highly recommended to achieve your desired profitability. Brokers and investors have highlighted their pros and cons, so one must analyse them and decide accordingly.

Open a demat account on Univest now to initiate your investment journey!

FAQs on Sai Parenteral’s IPO

How is the Sai Parenteral’s IPO?

Currently, on 24th March 2026, the Sai Parenteral’s GMP (Grey Market Premium) stands at ₹0. It indicates that the estimated listing price could be ₹392.00 per share. It is a book-building IPO of ₹408.79 per share. The face value of each share of Sai Parenteral is ₹10. 

What is the Sai Parenteral’s IPO price?

The Sai Parenteral’s IPO issue price band is set at ₹372 to ₹392 per share. 

Is the Sai Parenteral’s IPO a good investment?

Sai Parenteral’s Limited’s revenue increased by 5%, from ₹10.99 crore in March 2024 to ₹14.17 crore in March 2025. Moreover, the company’s PAT increased by 4% from ₹2.39 crore in March 2024 to ₹2.52 crore in March 2025.

Who is the registrar of the Sai Parenteral’s IPO?

Bigshare Services Private Limited is the registrar for Sai Parenteral’s IPO, awaiting the allotment process and initiating refunds. For any queries regarding Bigshare Services Limited at ipo@bigshareonline.com or +91-22-6263 8200.

What is the issue size of Sai Parenteral’s IPO? 

Sai Parenteral’s IPO is a bookbuilding IPO of ₹408.79 crores. Moreover, the IPO is set to open on 24th March 2026 and close on 27th March 2026. 

Disclaimer: The above information is compiled from authentic sources and is just for informational purposes. To have detailed information about the Sai Parenteral’s IPO, download the Sai Parenteral’s IPO RHP and Sai Parenteral’s IPO DRHP. Conduct your research before investing in IPOs to avoid significant losses. You can also consult your financial advisor.

Recent Articles

Novus Loyalty IPO GMP Day 3

Novus Loyalty IPO Subscription Status Day 3

Rajputana Stainless IPO Listing Preview

Innovision IPO Listing Preview